Back
Exhaled and non-exhaled non-invasive markers for assessment of respiratory inflammation in patients with stable COPD and healthy smokers.
G. Santini, N. Mores, R. Shohreh, S. Valente, M. Dabrowska, A. Trové, G. Zini, P. Cattani, L. Fuso, A. Mautone, C. Mondino, G. Pagliari, A. Sala, G. Folco, M. Aiello, R. Pisi, A. Chetta, M. Losi, E. Clini, G. Ciabattoni, P. Montuschi
J Breath Res 2016 Jan;10(1):017102.
PubMed: 26814886
Abstract
We aimed at comparing exhaled and non-exhaled non-invasive markers of respiratory inflammation in patients with chronic obstructive pulmonary disease (COPD) and healthy subjects and define their relationships with smoking habit. Forty-eight patients with stable COPD who were ex-smokers, 17 patients with stable COPD who were current smokers, 12 healthy current smokers and 12 healthy ex-smokers were included in a cross-sectional, observational study. Inflammatory outcomes, including prostaglandin (PG) E2 and 15-F2t-isoprostane (15-F2t-IsoP) concentrations in exhaled breath condensate (EBC) and sputum supernatants, fraction of exhaled nitric oxide (FENO) and sputum cell counts, and functional (spirometry) outcomes were measured. Sputum PGE2 was elevated in both groups of smokers compared with ex-smoker counterpart (COPD: P
Associated compounds:
Compound Name
with link to compound page |
Structure | Number of references |
---|---|---|
8-epi-PGF2alpha | 120 |